newly diagnosed FLT3-mutated AML patient Ͻ60 years was estimated at $114,193 compared to $105,819 for patients with non-FLT3-mutated AML. As early mortality and early retirement were not included in indirect costs, these may be underestimated. CONCLUSIONS: FLT3-mutated AML potentially represents a greater per-patient burden than non-FLT3-mutated AML due to shorter survival and greater use of stem cell transplants. Investigational treatments targeting the FLT3 mutation may provide an additional therapeutic option and have the potential to improve clinical outcomes.
OBJECTIVES: Postherpetic neuralgia (PHN) is a painful, chronic condition. Gabapentin and pregabalin are common first-line medications for PHN and must be titrated over time to effective doses. Individuals with PHN may augment therapy with opioids to control pain. Pain management for PHN can require substantial healthcare resources. The study objective was to evaluate costs for persons with PHN. METHODS: This retrospective claims database analysis used medical and pharmacy claims data and enrollment information for adult commercial and Medicare Advantage enrollees in a large, national US health plan. Patients had Ն1 pharmacy claim for gabapentin or pregabalin from January 2006 -February 2009; the date of the first claim was the index date. Patients also had diagnosis codes for PHN (ICD-9-CM 053.1x) on or within 2 days after the index date; and 6-month and 12month pre-and post-index periods, respectively, during which they were continuously enrolled. Total medical, outpatient pharmacy, and health care (medical ϩ pharmacy) post-index costs per patient with PHN per month were compared between gabapentin and pregabalin cohorts. RESULTS: The study population comprised 1645 patients, 939 in the gabapentin cohort and 706 in the pregabalin cohort; 77.6% were commercial enrollees and 22.4% were Medicare Advantage enrollees. The mean (standard deviation) monthly healthcare costs were $1,749 ($6,117) for the gabapentin cohort and $1,570 ($4,935) for the pregabalin cohort (pϭ0.512). Mean monthly medical costs were $1326 ($5831) in the gabapentin cohort and $985 ($4,753) in the pregabalin cohort (pϭ0.192). The pregabalin cohort had higher mean monthly pharmacy costs ($585 [$727]) than did the gabapentin cohort ($423 [$755], pϽ0.001). CONCLUSIONS: Health care costs for patients with PHN are substantial: approximately $1700 per person with PHN per month, and approximately $20,000 per year. Health care costs between the gabapentin and pregabalin cohorts were not significantly different despite significantly different mean pharmacy costs.
PSY22 HEALTH CARE COSTS FOR INFLAMMATORY BOWEL DISEASE PATIENTS WHO ARE ADHERENT VERSUS NON-ADHERENT WITH INFLIXIMAB THERAPY

OBJECTIVES:
Prior research evaluated the impact of infliximab (IFX) adherence on resource use and costs in Crohn's disease (CD). Purpose was to examine the association between adherence and all-cause healthcare costs among those who are treated with IFX for inflammatory bowel disease (IBD). METHODS: Patients with Ͼ1 claims for IFX initiated between January 1, 2006 to December 31, 2009 who had Ͼ2 IBD diagnoses of Crohn's disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC; ICD-9-CM: 556.XX) during the pre-index period were identified from Thomson Reuters Marketscan ® Databases. Patients had to be Ͼ18 years, continuously enrolled for 12 months before and after IFX initiation, and had no prior use of IFX during 360days pre-index. Patients with prior biologic therapy or rheumatoid arthritis (ICD-9-CM: 714.XX) were excluded. Adherent group was classified as having a medication possession ratio (MPR) of Ͼ80%; non-adherent group had an MPRϽ80%. Differences between the adherent and non-adherent groups were assessed using propensity-weighted general linear models. RESULTS: A total of 1,646 IBD patients were identified (945 CD; 701 UC) with a mean (SD) age of 44.4 (15.6) and 48.3% were female. Of these, 41% were adherent and 59% were non-adherent. Propensityweighted mean total healthcare costs excluding IFX were $13,424 vs. $32,522 (PϽ0.0001) for the adherent vs. non-adherent groups. Mean all-cause component costs were $2,458 vs. $17,634 (PϽ0.0001) for hospitalizations, $7,357 vs. $10,909 (PϽ0.0001) for outpatient visits, and $236 vs. $458 (PϽ0.0001) for ER visits in the adherent vs. non-adherent groups, respectively; total costs (componentϩ IFX) were also significantly lower in the adherent group. No significant differences were observed in other prescription costs. CONCLUSIONS: Medication adherence was associated with significantly lower total healthcare costs in patients treated with IFX for IBD. These differences may be explained by reduced hospitalization, outpatient, and ER costs observed in the adherent vs. non-adherent groups. 
PSY23
BURDEN OF ILLNESS OF AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) IN THE UNITED STATES
OBJECTIVES:
Little data are available on the burden of ASM, a subtype of systemic mastocytosis (SM) and severe form of mast cell disease that may progress to mast cell leukemia. This study reviewed the literature in order to estimate the burden of ASM in the US. METHODS: A systematic literature review was conducted to identify publications from 2000-2011; 181 citations were identified and 6 articles abstracted. The US population-level burden of ASM was estimated using an Excel model. Direct treatment costs were calculated from treatment patterns described in identified publications. RESULTS: ASM involves multiple organ systems, resulting in potentially severe symptoms/conditions including anaphylaxis/allergic reactions, osteoporosis, hepatomegaly, splenomegaly, gastrointestinal symptoms, fatigue, and weight loss. There is no known cure for ASM. Median survival was 41 months in a published cohort study. No publications were identified providing US epidemiology data. Two estimates were calculated for the prevalence of ASM in the US in 2010: 616 and 1,220. A global prevalence rate of 0.2/100,000 resulted in 616 cases. An SM prevalence rate of 3.3/100,000 (assuming 12% ASM) resulted in 1,220 cases. Incidence was estimated at 111 cases in 2010 using an SM incidence rate of 0.3/100,000 (assuming 12% ASM). The proportion of ASM/SM cases ranged from 7-18% in the literature with 12% from the largest study. No studies were identified examining the economic burden of ASM. In this model, direct monthly per-patient costs were estimated between $5232 and $8741. These are likely underestimated as a result of limited resource utilization information in the literature. CONCLUSIONS: These results provide preliminary estimates for the burden of ASM in the UNITED STATES. Additional research can assist in further quantifying these estimates. In addition, it is likely that ASM patients experience tremendous indirect costs due to the symptomatic burden of the disease and further evaluation is warranted. 
PSY24 ASSOCIATION OF PATIENT COST OR REIMBURSEMENT CHALLENGES WITH HEALTH CARE RESOURCE UTILIZATION, QUALITY OF LIFE, AND WORK PRODUCTIVITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
OBJECTIVES:
To evaluate the association of patient cost or reimbursement challenges with healthcare resource utilization, quality of life (QoL), and work productivity among patients with inflammatory bowel disease (IBD). METHODS: A syndicated study of IBD patients in the US was conducted. Patients Ն18 years of age were recruited via the National Health and Wellness Survey and Lightspeed Research Panel. Patients completed a survey during August-November 2010 in which they were asked if they experienced cost or reimbursement challenges related to prescription medication. The Medical Outcomes Study (MOS) IBD questionnaire was used to assess QoL. Work productivity was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. To measure health care resource utilization, the number of provider, emergency room (ER) and hospital visits in the past six months was collected. Bivariate differences between the patient groups (those with cost or reimbursement issues versus those without) for resource utilization, QoL, and work impairment were assessed using chi-square tests for categorical variables and t-tests for continuous variables. RESULTS: Of 1098 IBD patients currently receiving prescription medication, 21% (nϭ231) reported that cost had previously prevented them from taking medication. Among patients who had ever taken prescription medication (nϭ1343), 13% (nϭ178) reported ever having a problem getting reimbursed for medication. Sixty-eight of these patients (38%) indicated their medication was not covered by insurance. Patients reporting cost or reimbursement issues had a higher probability of having provider, ER and hospital visits in the prior six months (all pϽ0.05). Furthermore, these patients reported greater work impairment and lower QoL (both pϽ0.05). CONCLUSIONS: Among IBD patients, cost or reimbursement challenges may be associated with more resource A102 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6 utilization, lower QoL and greater work impairment. Additional research is warranted to further characterize the impact of cost and reimbursement on patient outcomes. Index date was the date of the first SLE diagnosis. All patients were continuously enrolled for Ն6 months before and Ն12 months after index date and followed until the earliest of inpatient death, end of enrollment, or end of study. Mild, moderate, and severe flares were identified in the follow-up period. Costs attributable to flares were measured during 30 days following a flare. If a flare of higher severity occurred within 30 days, the length was limited to the period up to the start of the new flare. RESULTS: 14,262 patients met the study criteria and 97% experienced at least one flare during an average follow-up of 39 months (3,540 had severe, 9,597 had moderate, and 669 had mild flares as their most severe flares). Mean costs per flare were $11,716, $562 and $129 for severe, moderate, and mild flares, respectively. Patients with Ն1 severe flares during follow-up had 1.7 inpatient (IP) admissions, 3.5 emergency room (ER) visits, and 16.0 outpatient (OP) visits with a total medical cost of $49,754per year. Patients with Ն1 moderate flares but no severe flares had 0.9 IP admissions, 2.4 ER visits, and 12.8 OP visits with a cost of $21,941. Patients with only mild flares had the least HRU of 1.0 IP admission, 1.5 ER visits, and 7.5 OP visits with a cost of $17,574. Patients with severe and moderate but no mild flares and patients with severe flares only incurred the highest annual cost ($66,412 and $74,491, respectively) . CONCLUSIONS: Flares occurred in almost all SLE patients and were associated with a significant economic burden.
PSY25 HEALTH CARE RESOURCE UTILIZATION (HRU) AND COSTS ASSOCIATED WITH FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A MEDICAID POPULATION IN THE UNITED STATES
PSY26 COSTS AND OUTCOMES OF PATIENTS WITH HAEMOPHILIA A (HA) AND FACTOR VIII INHIBITORS TREATMENT: THE IMMUNE TOLERANCE AND ECONOMICS RETROSPECTIVE REGISTRY (ITER) RESULTS
Gringeri A 1 , Scalone L 2 , Cortesi PA 2 , Rocino A 3 , Mantovani LG 4 1 University of Milan -IRCCS Cà Granda Maggiore Policlinic Hospital, Milano, Italy, 2 University of Milano-Bicocca, Monza (MB), Italy, 3 Ospedale S. Giovanni Bosco, Napoli, Italy, 4 Federico II University of Naples, Naples, Italy OBJECTIVES: Immune tolerance induction (ITI) is generally accepted as first choice treatment to eradicate inhibitors in hemophilia A patients. Little is known about the outcomes and cost consequences of this treatment option. METHODS: The Immune Tolerance and Economics Retrospective (ITER) study is an observational, retrospective, multicentre, multinational study aiming to estimate cost of treatment in hemophilia A patients, undergoing ITI. Data on hemostatic treatment given in the following time periods were collected: up to 12 months before the diagnosis of Inhibitors, between Inhibitors diagnosis and ITI start, during ITI, and 12 months after the end of ITI. Costs of treatment were calculated in the perspective of the third party payer and expressed as mean €/patient-month. RESULTS: Seventy-one valid patients, with median age at ITI startϭ3.8 (0.4-41) years, were enrolled. Before ITI the median Inhibitors peak titre was 18.5 (0.80-704) BU. ITI was applied for a mean of 1.85 (0.1-14.0) years and was successful in 84.5% pts. Before Inhibitors diagnosis, patients cost was 670.2 €/patient-month. Cost was 3,188€/ patient-month between the Inhibitors diagnosis and ITI start (92.1% for bypassing agents), and 60,078€ during ITI (76.8% for ITI, 19.4% for extra FVIII treatment, 3.8% for extra treatment with bypassing agents). The mean cost after ITI was 13,211€/patient-month. CONCLUSIONS: ITI applied on patients with the characteristics of those involved in the ITER study is successful in 84% of them at a mean cost of 60,000€/patient-month during ITI, plus 13,000€/patient-month through 1 year later. Further research is encouraged to value long term benefits and costs attributable to ITI versus other treatment options, in order to identify the most efficient treatment for the patients and for the health care system.
PSY27 COST EFFECTIVENESS OF TREATMENT WITH ETANERCEPT OR USTEKINUMAB FOR MODERATE TO SEVERE PSORIASIS
Villacorta R, Hay J, Messali A University of Southern California, Los Angeles, CA, USA OBJECTIVES: Limited information is available on the cost effectiveness of newer biologic agents for treatment of psoriasis. The objective of this study is, from a United States societal perspective, to compare the cost-effectiveness of etanercept and ustekinumab therapy in patients with moderate-to-severe psoriasis based on head-to-head clinical trial information. METHODS: A Markov model was constructed to simulate the incremental cost per quality-adjusted life year gained. Costs were estimated from the societal perspective in the United States over a time horizon of five years. All cost and effectiveness estimates were obtained from the relevant literature. An annual discount rate of 3% was applied to costs and qualityadjusted life years. All costs were adjusted to 2011 US dollars. One-way and threshold sensitivity analyses assessed the robustness of model results. RESULTS: In the base case, over a 5-year time horizon, ustekinumab 45 mg was dominant versus etanercept 50 mg. The base case incremental cost-effectiveness ratio (ICER) comparing ustekinumab 90 mg with etanercept 50 mg averaged $267,761 per QALY gained. The ICER comparing ustekinumab 90 mg with ustekinumab 45 mg averaged $915,179 per QALY gained. ICERs were quite sensitive to unit prices for ustekinumab and etanercept. CONCLUSIONS: Given the limitations of the available data, ustekinumab 45 mg was dominant over etanercept 50 mg for a five-year time horizon, whereas ustekinumab 90 mg was more costly and marginally more effective than etanercerpt 50 mg. Ustekinumab 90 mg would not be considered cost effective using a US willingness-to-pay threshold of $120,000-150,000 per QALY.
PSY28
COST-EFFECTIVENESS ANALYSIS OF CELECOXIB IN THE TREATMENT OF CHRONIC PAIN IN PATIENTS WITH OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS VERSUS THE USE OF ETORICOXIB OR LUMIRACOXIB IN MEXICO
Vargas-valencia JJ 1 , Orrantia-Gradín R 2 , Muciño-Ortega E 2 , Galindo-Suárez RM 2 1 Econopharma Consulting S. A. de C.V., Mexico City, Mexico, 2 Pfizer S.A. de C.V., Mexico City, Mexico OBJECTIVES: Patients with chronic pain due to osteoarthritis (OA) or rheumatoid arthritis (RA) do not often obtain adequate relief or experience unacceptable side effects due their pain-control treatments. The objective of this study was to perform a cost-effectiveness analysis comparing celecoxib, etoricoxib and lumiracoxib in the treatment of chronic pain in patients with OA and RA, from the Mexican Social Security Institute (IMSS) perspective. METHODS: A decision-tree model (12-weeks time horizon) was used to compare pain reduction and direct medical costs associated to competing alternatives. A systematic literature review was performed to identify the pain reduction (reported through visual analogue scales) and adverse events (AE) incidence rate associated. Comparators were: celecoxib 200mg/ day, etoricoxib 90mg/day and lumiracoxib 100mg/day for patients with OA and RA. A meta-analysis with selected publications (nϭ10) was performed. Resource utilization was extracted from clinical practice guidelines and unit costs were retrieved from IMSS official sources. Probabilistic sensitivity analysis was performed. Acceptability curves were developed. RESULTS: Pain reductions vs. placebo were: celecoxib 14.18% (CI95% 10.48-17.87, pϽ0.00001); etoricoxib 12.70% (7.67-17.73, pϽ0.00001) and lumiracoxib 9.47% (7.17-11.77, pϽ0.00001). Differences between celecoxib and lumiracoxib was meaningful (pϽ0.05). The odds ratios of AE incidence vs. placebo were: 1.06 (0.77-1.46, pϭ0.37); 1.09 (0.87-1.36, pϭ0.73) and 1.44 (0.88-2.34, pϭ0.14), respectively. The expected medical costs (2011 US$) were: $197.93 (Ϯ$9.52); $221.54 (Ϯ$7.06) and $306.65 (Ϯ$12.86), respectively. The cost of management of AE contributed with $101.28, $95.00 and $146.17 of the overall expected costs, respectively. In regards to etoricoxib (basecase), celecoxib showed to be a cost-saving strategy with a cost-effective proportion of 76.7% (74.1%-79.3%); while lumiracoxib was the less effective and more costly strategy. CONCLUSIONS: At IMSS, celecoxib patients who suffer OA or RA would reach a higher incremental reduction in pain intensity at 12 weeks reducing overall costs in comparison to etoricoxib.
